{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:35:01Z","timestamp":1787668501044,"version":"build-2736575974"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Several commercial methods exist for the molecular detection of\n            <jats:named-content content-type=\"genus-species\">Chlamydia trachomatis<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">Neisseria gonorrhoeae<\/jats:named-content>\n            in clinical samples. Here we evaluated the performance characteristics of the newly FDA-cleared Abbott RealTi\n            <jats:italic>m<\/jats:italic>\n            e CT\/NG assay (where \u201cCT\u201d stands for\n            <jats:named-content content-type=\"genus-species\">Chlamydia trachomatis<\/jats:named-content>\n            and \u201cNG\u201d stands for\n            <jats:named-content content-type=\"genus-species\">Neisseria gonorrhoeae<\/jats:named-content>\n            ) that uses the automated\n            <jats:italic>m<\/jats:italic>\n            2000 molecular platform. Results were compared to those of the Roche Cobas Amplicor CT\/NG assay. A total of 926 cervical swab, 45 female urine, 6 male urethral swab, and 407 male urine specimens from 1,384 patients were examined. After resolving all Roche\n            <jats:named-content content-type=\"genus-species\">N. gonorrhoeae<\/jats:named-content>\n            -positive results with two additional real-time PCR assays, we found that the agreement between the assays was excellent. For urine samples, there was 99.6% positive agreement and 97.7% negative agreement for\n            <jats:named-content content-type=\"genus-species\">C. trachomatis<\/jats:named-content>\n            , and for male urine samples, there was 100% positive agreement and 99.7% negative agreement for\n            <jats:named-content content-type=\"genus-species\">N. gonorrhoeae<\/jats:named-content>\n            . For cervical swab samples, there was 98.8% positive agreement and 98.5% negative agreement for\n            <jats:named-content content-type=\"genus-species\">C. trachomatis<\/jats:named-content>\n            , and there was 96.6% positive agreement and 99.8% negative agreement for\n            <jats:named-content content-type=\"genus-species\">N. gonorrhoeae<\/jats:named-content>\n            . In limiting dilution analyses, we found that the Abbot assay was more sensitive than the Roche assay for both\n            <jats:named-content content-type=\"genus-species\">C. trachomatis<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">N. gonorrhoeae<\/jats:named-content>\n            . In addition, there appeared to be an enhanced ability of the Abbott assay to detect dual infections, especially in the presence of large amounts of\n            <jats:named-content content-type=\"genus-species\">N. gonorrhoeae<\/jats:named-content>\n            and small amounts of\n            <jats:named-content content-type=\"genus-species\">C. trachomatis<\/jats:named-content>\n            organisms. In summary, we conclude that the Abbott RealTi\n            <jats:italic>m<\/jats:italic>\n            e CT\/NG assay is an accurate and automated new addition to the available testing options for\n            <jats:named-content content-type=\"genus-species\">C. trachomatis<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">N. gonorrhoeae<\/jats:named-content>\n            .\n          <\/jats:p>","DOI":"10.1128\/jcm.02595-10","type":"journal-article","created":{"date-parts":[[2011,2,17]],"date-time":"2011-02-17T03:37:05Z","timestamp":1297913825000},"page":"1294-1300","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":54,"title":["Evaluation of the Abbott RealTi\n            <i>m<\/i>\n            e CT\/NG Assay in Comparison to the Roche Cobas Amplicor CT\/NG Assay"],"prefix":"10.1128","volume":"49","author":[{"given":"Annie","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinfang","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Kirby","sequence":"additional","affiliation":[{"name":"Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Abbot Molecular Inc. July 2008. Abbott RealTi m e CT\/NG in vitro test ref. 8L07 51-608201\/R1 package insert. Abbott Molecular Inc. Des Plaines IL."},{"key":"e_1_3_2_3_2","unstructured":"Blackhawk Biosystems Inc. September 2006. AmpliTrol CT\/GC package insert. Blackhawk Biosystems Inc. San Ramon CA."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.5.2231-2235.2005"},{"key":"e_1_3_2_5_2","unstructured":"CLSI. 2008. User protocol for evaluation of qualitative test performance; approved guideline 2nd ed. CLSI document EP12-A2. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1998.01101.x"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01019-10"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.1.304-309.2003"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00043-08"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01956-06"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.10.3544-3549.2000"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.6.2027-2029.2000"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0890-8508(06)80003-4"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/mp.51.3.149"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.2.835-837.2003"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1099\/mic.0.27625-0"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkn408"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0463.2005.apm_206.x"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-2-200707170-00172"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.9.3092-3098.2001"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/00313020600928253"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-004-1170-0"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.2353\/jmoldx.2006.050045"},{"issue":"11","key":"e_1_3_2_24_2","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2006","volume":"55","author":"Workowski K. A.","year":"2006","unstructured":"WorkowskiK. A. BermanS. M.. 2006. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recommend. Rep. 55(RR-11):1\u201394.","journal-title":"MMWR Recommend. Rep."},{"issue":"12","key":"e_1_3_2_25_2","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2010","volume":"59","author":"Workowski K. A.","year":"2010","unstructured":"WorkowskiK. A. BermanS. M.. 2010. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recommend. Rep. 59(RR-12):1\u2013110.","journal-title":"MMWR Recommend. Rep."}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.02595-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.02595-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T12:59:29Z","timestamp":1646485169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.02595-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1128\/JCM.02595-10"],"URL":"https:\/\/doi.org\/10.1128\/jcm.02595-10","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"2010-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-02-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-04-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}